AKCEA THERAPEUTICS, INC.
AKCEA THERAPEUTICS, INC. (AKCA): 7 pipeline candidates · ~35 mo cash runway · 4 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
35.0 months
D/E 0.10 · 0% dilution
Lead: Approved
7 candidates
N/A
N/A
A transparent, data-derived signal for AKCEA THERAPEUTICS, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$138.1M
Quarterly Burn
$33.4M
Runway
35.0 mo
Revenue
$22.4M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (7 candidates)
| Drug | Phase |
|---|---|
| akcea-angptl3-lrx | Phase 2 |
| akcea-apo-lrx | Phase 3 |
| akcea-apociii-lrx | Phase 2 |
| akcea-ttr-lrx | Phase 3 |
| inotersen | — |
| tegsedi | Approved |
| waylivra | Approved |
Frequently asked questions
How many drug candidates are in AKCEA THERAPEUTICS, INC.'s pipeline?
AKCEA THERAPEUTICS, INC. (AKCA) has 7 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is AKCEA THERAPEUTICS, INC.'s lead drug candidate?
AKCEA THERAPEUTICS, INC.'s most advanced tracked candidate is akcea-angptl3-lrx (Phase 2) for cardiovascular and metabolic diseases.
What is AKCEA THERAPEUTICS, INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, AKCEA THERAPEUTICS, INC. has approximately 35.0 months of cash runway.
Get the full picture on AKCEA THERAPEUTICS, INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.